全球HER2抗体市场规模、份额、趋势和成长分析报告（2026-2034年）

预计 HER2 抗体市场将从 2025 年的 315.8 亿美元成长到 2034 年的 579.1 亿美元，2026 年至 2034 年的复合年增长率为 6.97%。

由于HER2阳性癌症（尤其是乳癌和胃癌）的发生率不断上升，全球HER2抗体市场正经历显着成长。 HER2抗体是标靶治疗，旨在抑制人类表皮生长因子受体2 (HER2)，HER2在某些癌细胞增殖中起着至关重要的作用。这些治疗方法已显着改善了HER2阳性肿瘤患者的治疗效果。

製药公司正积极研发针对HER2受体的创新单株抗体和抗体药物复合体。标靶治疗和免疫疗法的进步正在拓展癌症患者的治疗选择。此外，精准医疗和伴随诊断的日益普及，也使得医疗服务提供者更容易识别最有可能从HER2标靶治疗中获益的患者。

随着肿瘤学领域研究的不断深入，市场预计将持续成长。新型HER2标靶治疗和联合治疗方案正在临床试验中进行探索。随着癌症诊断技术的进步和个人化治疗策略的普及，全球对HER2抗体的需求将持续成长。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球HER2抗体市场：依HER2抗体类型划分

• 市场分析、洞察与预测
• 单株抗体
• 人源化抗体
• 双特异性抗体
• 奈米抗体

第五章：全球HER2抗体市场：依作用机制划分

• 市场分析、洞察与预测
• HER2抑制
• 免疫调节
• 标靶药物递送

第六章：全球HER2抗体市场：依应用领域划分

• 市场分析、洞察与预测
• 乳癌
• 胃癌
• 其他固态肿瘤
• 诊断用途

第七章：全球HER2抗体市场：依通路划分

• 市场分析、洞察与预测
• 医院药房
• 零售药房
• 网路药房
• 专业药品批发商

第八章：全球HER2抗体市场：依最终用户划分

• 市场分析、洞察与预测
• 医院
• 肿瘤诊所
• 研究机构
• 製药公司

第九章 全球HER2抗体市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第十章 竞争格局

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十一章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Novartis
  • Pfizer
  • Roche
  • Abnova
  • InvivoGen
  • Celltrion
  • Biocon
  • Novus Biologicals
  • Amgen
  • Genentech

The HER2 Antibodies Market size is expected to reach USD 57.91 Billion in 2034 from USD 31.58 Billion (2025) growing at a CAGR of 6.97% during 2026-2034.

The global HER2 antibodies market is experiencing strong growth due to the increasing prevalence of HER2-positive cancers, particularly breast and gastric cancers. HER2 antibodies are targeted therapies designed to block the human epidermal growth factor receptor 2 (HER2), which plays a key role in the growth of certain cancer cells. These therapies have significantly improved treatment outcomes for patients with HER2-positive tumors.

Pharmaceutical companies are actively developing innovative monoclonal antibodies and antibody-drug conjugates targeting HER2 receptors. Advances in targeted therapy and immunotherapy are expanding treatment options for cancer patients. Additionally, the growing adoption of precision medicine and companion diagnostics is helping healthcare providers identify patients who are most likely to benefit from HER2-targeted therapies.

In the future, the market is expected to grow as research in oncology continues to advance. New HER2-targeted therapies and combination treatment approaches are being explored in clinical trials. As cancer diagnosis improves and personalized treatment strategies become more common, the demand for HER2 antibodies will continue to increase globally.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type of HER2 Antibodies

• Monoclonal Antibodies
• Humanized Antibodies
• Bispecific Antibodies
• Nanobodies

By Mechanism of Action

• HER2 Inhibition
• Immune Modulation
• Targeted Drug Delivery

By Application Areas

• Breast Cancer
• Gastric Cancer
• Other Solid Tumors
• Diagnostic Applications

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Specialty Drug Distributors

By End-User

• Hospitals
• Oncology Clinics
• Research Institutions
• Pharmaceutical Companies

COMPANIES PROFILED

• Novartis, Pfizer, Roche, Abnova, InvivoGen, Celltrion, Biocon, Novus Biologicals, Amgen, Genentech
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL HER2 ANTIBODIES MARKET: BY TYPE OF HER2 ANTIBODIES 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type Of Her2 Antibodies
• 4.2. Monoclonal Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Humanized Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Bispecific Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Nanobodies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL HER2 ANTIBODIES MARKET: BY MECHANISM OF ACTION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Mechanism Of Action
• 5.2. HER2 Inhibition Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Immune Modulation Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Targeted Drug Delivery Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL HER2 ANTIBODIES MARKET: BY APPLICATION AREAS 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Application Areas
• 6.2. Breast Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Gastric Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Other Solid Tumors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Diagnostic Applications Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL HER2 ANTIBODIES MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Distribution Channel
• 7.2. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Retail Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Online Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Specialty Drug Distributors Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL HER2 ANTIBODIES MARKET: BY END-USER 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast End-user
• 8.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Oncology Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Research Institutions Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.5. Pharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL HER2 ANTIBODIES MARKET: BY REGION 2022-2034(USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Type Of Her2 Antibodies
  • 9.2.2 By Mechanism Of Action
  • 9.2.3 By Application Areas
  • 9.2.4 By Distribution Channel
  • 9.2.5 By End-user
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Type Of Her2 Antibodies
  • 9.3.2 By Mechanism Of Action
  • 9.3.3 By Application Areas
  • 9.3.4 By Distribution Channel
  • 9.3.5 By End-user
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Russia
  • 9.3.11 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Type Of Her2 Antibodies
  • 9.4.2 By Mechanism Of Action
  • 9.4.3 By Application Areas
  • 9.4.4 By Distribution Channel
  • 9.4.5 By End-user
  • 9.4.6 India
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 Australia
  • 9.4.10 South East Asia
  • 9.4.11 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Type Of Her2 Antibodies
  • 9.5.2 By Mechanism Of Action
  • 9.5.3 By Application Areas
  • 9.5.4 By Distribution Channel
  • 9.5.5 By End-user
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 South East Asia
  • 9.5.11 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Type Of Her2 Antibodies
  • 9.6.2 By Mechanism Of Action
  • 9.6.3 By Application Areas
  • 9.6.4 By Distribution Channel
  • 9.6.5 By End-user
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL HER2 ANTIBODIES INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 Novartis
  • 11.2.2 Pfizer
  • 11.2.3 Roche
  • 11.2.4 Abnova
  • 11.2.5 InvivoGen
  • 11.2.6 Celltrion
  • 11.2.7 Biocon
  • 11.2.8 Novus Biologicals
  • 11.2.9 Amgen
  • 11.2.10 Genentech